LIMN
Liminatus Pharma, Inc.
$0.1220
-10.29%
$5.5M
No data for this timeframe.
Vol
Market Cap$5.5M
Cap SizeNano Cap
Inst. Holders7 funds
Inst. Value$141.8K
Inst. Activity0 buys / 1 sells
Reddit Sentiment65° Warm
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001971387·Prev Close $0.1360
Recent Activity
Inst.
BANK OF AMERICA CORP — TRIM
44 shares ($27.00)
Inst.
UBS Group AG — ADD
40,526 shares ($67.7K)
Jun 2, 2026
short_volume
Short Volume: LIMN — 58.3% short (4.1M / 7.1M)
Short: 4,134,309 | Exempt: 16,353 | TRF Vol: 7,094,586 | Short Ratio: 58.3% | Off-exchange volume (d
May 22, 2026
Press
Liminatus Pharma received a Nasdaq delisting notice after failing to regain compliance with the $50M market value of lis
Impact 8/10
Mar 17, 2026
Press
Liminatus Pharma announced plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking antibo
Impact 4/10
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITADEL ADVISORS LLC | $116.5K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.7K | — |
| Vanguard Personalized Indexing Management, | $6.0K | — |
| VANGUARD FIDUCIARY TRUST CO | $4.0K | — |
| STATE STREET CORP | $3.3K | — |
Reddit Sentiment
65°▲
Warm
Bearish
Neutral
Bullish
7 institutional holders with $141.8K total value (824,671 shares) as of 2026-Q1. Top holders: CITADEL, VANGUARD, Vanguard.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 677,518 | $116.5K | 82.2% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 50,440 | $8.7K | 6.1% | — |
| 3 | Vanguard Personalized Indexing Management, LLC | 34,706 | $6.0K | 4.2% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 22,984 | $4.0K | 2.8% | — |
| 5 | STATE STREET CORP | 19,000 | $3.3K | 2.3% | — |
| 6 | BlackRock, Inc. | 13,254 | $2.3K | 1.6% | — |
| 7 | CITIGROUP INC | 6,769 | $1.2K | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 68 | 44 | -35.3% | $27.00 | 2025-Q4 |
| UBS Group AG | ADD | 31,486 | 40,526 | +28.7% | $67.7K | 2025-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
65°
Warm
Bearish
Neutral
Bullish
6 mentions
4 bullish
1 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 9, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
$LIMN +16% — InnocsAI merger to bolt on CAR-T pipeline
▲ 1
💬 1
⚡ 0.5
The Perfect Catch 🎯 straight to max target then crash
▲ 2
💬 2
⚡ 0.0
Jun 2, 2026
short_volume
Short Volume: LIMN — 58.3% short (4.1M / 7.1M)
Short: 4,134,309 | Exempt: 16,353 | TRF Vol: 7,094,586 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 22, 2026
delisting
Liminatus Pharma Announces Nasdaq Delisting Notification
<p align="justify">FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today an
Apr 23, 2026
short_volume
Short Volume: LIMN — 63.3% short (0.4M / 0.7M)
Short: 443,657 | Exempt: 48,349 | TRF Vol: 700,922 | Short Ratio: 63.3% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: LIMN — 60.2% short (1.1M / 1.9M)
Short: 1,115,083 | Exempt: 203,339 | TRF Vol: 1,852,330 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: LIMN — 55.5% short (15.2M / 27.3M)
Short: 15,170,297 | Exempt: 192,892 | TRF Vol: 27,324,890 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
Mar 17, 2026
fda
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Liminatus announces plan to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody.
Feb 5, 2026
short_interest
FTD: LIMN — 394,170 shares ($0.6M) failed to deliver
Settlement: 20260205, Price: $1.43, FTD Value: $563,663.1, LIMINATUS PHARMA INC CL A (DE)
Feb 4, 2026
short_interest
FTD: LIMN — 2,076,007 shares ($2.2M) failed to deliver
Settlement: 20260204, Price: $1.07, FTD Value: $2,221,327.49, LIMINATUS PHARMA INC CL A (DE)